Publications by authors named "Paulatsya Joshi"
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting IL-17F and IL-17A, is being tested as a treatment for moderate-to-severe hidradenitis suppurativa, a condition with limited treatment options.
- The BE HEARD I and II trials were 48-week, randomized, double-blind studies that evaluated the efficacy and safety of various dosing regimens of bimekizumab compared to a placebo in over 1,000 patients.
- Results showed significant improvement in patients receiving bimekizumab every 2 weeks, meeting the primary efficacy goal of at least a 50% reduction in disease symptoms by week 16.
Background: Tuberculin skin testing is simple and relatively inexpensive, but the specificity of PPD is affected by BCG vaccination.
Objective: Determine optimal dose and specificity of recombinant ESAT-6 and CFP-10 (C-Tb) produced in Lactococcus lactis for diagnosis of M. tuberculosis infection.